Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline Review, H1 2017’, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

The report reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutics and enlists all their major and minor projects

The report assesses Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

AB Science SA

AbbVie Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics Sarl

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Affichem SA

Agios Pharmaceuticals Inc

Aileron Therapeutics Inc

AIMM Therapeutics BV

Alexion Pharmaceuticals Inc

Altor BioScience Corp

Amgen Inc

Antigen Express Inc

Antisense Therapeutics Ltd

APIM Therapeutics AS

Aptevo Therapeutics Inc

Aptose Biosciences Inc

arGEN-X BV

Ariad Pharmaceuticals Inc

Arno Therapeutics Inc

Arog Pharmaceuticals Inc

Array BioPharma Inc

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

Asterias Biotherapeutics Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Athenex Inc

Aurigene Discovery Technologies Ltd

AVEO Pharmaceuticals Inc

Bayer AG

BCI Pharma

Bellicum Pharmaceuticals Inc

BerGenBio ASA

Bio-Cancer Treatment International Ltd

Bio-Path Holdings Inc

BioLineRx Ltd

BioSight Ltd

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

Cancer Therapeutics CRC Pty Ltd

Cantargia AB

Cantex Pharmaceuticals Inc

Cascadian Therapeutics Inc

Celgene Corp

Cell Medica Ltd

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellectis SA

Cellerant Therapeutics Inc

Cellular Biomedicine Group Inc

Celyad SA

CharlestonPharma LLC

Cielo Therapeutics Inc

ConverGene LLC

Critical Outcome Technologies Inc

CSPC Pharmaceutical Group Limited

CTI BioPharma Corp

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

DC Prime BV

Deciphera Pharmaceuticals LLC

eFFECTOR Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Company

Emercell SAS

EntreChem SL

EpiZyme Inc

Erytech Pharma SA

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

FLX Bio Inc

Forma Therapeutics Inc

Formula Pharmaceuticals Inc

Fortress Biotech Inc

Forty Seven Inc

Fujifilm Corp

Gamida Cell Ltd

Genentech Inc

Genoscience Pharma

Genosco Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

GlycoMimetics Inc

Glycostem Therapeutics BV

Golden Biotechnology Corp

H3 Biomedicine Inc

Hanmi Pharmaceuticals Co Ltd

Hybrigenics SA

Igenica Biotherapeutics Inc

IGF Oncology LLC

Ignyta Inc

Immune Pharmaceuticals Inc

Immune System Key Ltd

ImmunGene Inc

ImmunoGen Inc

Immunomedics Inc

Incyte Corp

Inflection Biosciences Ltd

Innovation Pharmaceuticals Inc

Interprotein Corp

Io Therapeutics Inc

Jasco Pharmaceuticals LLC

Jazz Pharmaceuticals Plc

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

JW Pharmaceutical Corp

Kainos Medicine Inc

Karyopharm Therapeutics Inc

Kiadis Pharma NV

Kite Pharma Inc

Komipharm International Co Ltd

Kura Oncology Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

MacroGenics Inc

Mateon Therapeutics Inc

MaxCyte Inc

medac GmbH

MediGene AG

MedImmune LLC

Medivir AB

MEI Pharma Inc

Merck & Co Inc

Merck KGaA

Merus NV

Millennium Pharmaceuticals Inc

Miltenyi Biotec GmbH

miRagen Therapeutics Inc

Mirati Therapeutics Inc

Moleculin Biotech Inc

MolMed SpA

NantKwest Inc

Nerviano Medical Sciences Srl

Neumedicines Inc

NewLink Genetics Corp

Novartis AG

NuCana BioMed Ltd

Omeros Corp

OncoImmune Inc

Onconova Therapeutics Inc

OncoTartis Inc

OncoTherapy Science Inc

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

Otsuka Holdings Co Ltd

Oxford BioTherapeutics Ltd

OXIS International Inc

Panacea Pharmaceuticals Inc

Pfizer Inc

Pharma Mar SA

Pharmascience Inc

Pharmedartis GmbH

Philogen SpA

Phylogica Ltd

Plexxikon Inc

Polaris Pharmaceuticals Inc

PTC Therapeutics Inc

Rafael Pharmaceuticals Inc

Resverlogix Corp

Rich Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

Sanofi

Sareum Holdings Plc

Seattle Genetics Inc

Selvita SA

Senhwa Biosciences Inc

Shire Plc

Sierra Oncology Inc

Sigma-Tau SpA

Sorrento Therapeutics Inc

Spectrum Pharmaceuticals Inc

Stemline Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Sunesis Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

SYNIMMUNE GmbH

Syros Pharmaceuticals Inc

TaiGen Biotechnology Co Ltd

Taiho Pharmaceutical Co Ltd

Takara Bio Inc

Takeda Pharmaceutical Company Ltd

Teva Pharmaceutical Industries Ltd

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Trillium Therapeutics Inc

Trovagene Inc

VasGene Therapeutics Inc

Vichem Chemie Research Ltd

Viralytics Ltd

Xencor Inc

Xenetic Biosciences Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 10

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview 11

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development 12

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment 71

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development 100

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles 218

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 1600

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 1612

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 1616

Appendix 1628

List of Tables

List of Tables

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Products under Development by Companies, H1 2017 (Contd..20), H1 2017

Products under Development by Companies, H1 2017 (Contd..21), H1 2017

Products under Development by Companies, H1 2017 (Contd..22), H1 2017

Products under Development by Companies, H1 2017 (Contd..23), H1 2017

Products under Development by Companies, H1 2017 (Contd..24), H1 2017

Products under Development by Companies, H1 2017 (Contd..25), H1 2017

Products under Development by Companies, H1 2017 (Contd..26), H1 2017

Products under Development by Companies, H1 2017 (Contd..27), H1 2017

Products under Development by Companies, H1 2017 (Contd..28), H1 2017

Products under Development by Companies, H1 2017 (Contd..29), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by 4SC AG, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by AB Science SA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by AbbVie Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Actinium Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by ADC Therapeutics Sarl, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Advenchen Laboratories LLC, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Aeglea BioTherapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Affichem SA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Agios Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Aileron Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by AIMM Therapeutics BV, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Alexion Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Altor BioScience Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Amgen Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Antigen Express Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Antisense Therapeutics Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by APIM Therapeutics AS, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Aptevo Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Aptose Biosciences Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by arGEN-X BV, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Ariad Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Arno Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Arog Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Array BioPharma Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Astellas Pharma Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Asterias Biotherapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Astex Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by AstraZeneca Plc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Atara Biotherapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Athenex Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Aurigene Discovery Technologies Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Bayer AG, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by BCI Pharma, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by BerGenBio ASA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Bio-Cancer Treatment International Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Bio-Path Holdings Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by BioLineRx Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by BioSight Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Blueprint Medicines Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Boston Biomedical Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Bristol-Myers Squibb Company, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Calithera Biosciences Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Cantargia AB, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Cantex Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Cascadian Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Celgene Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Cell Medica Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Celldex Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Cellectar Biosciences Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Cellectis SA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Cellerant Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Cellular Biomedicine Group Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Celyad SA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by CharlestonPharma LLC, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Cielo Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by ConverGene LLC, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Critical Outcome Technologies Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by CSPC Pharmaceutical Group Limited, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by CTI BioPharma Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by DC Prime BV, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by eFFECTOR Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Eisai Co Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Eli Lilly and Company, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Emercell SAS, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by EntreChem SL, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by EpiZyme Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Erytech Pharma SA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Esperance Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Exelixis Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Fate Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by FLX Bio Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Forma Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Formula Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Fortress Biotech Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Forty Seven Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Fujifilm Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Gamida Cell Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Genentech Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Genoscience Pharma, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Genosco Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Gilead Sciences Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by GlaxoSmithKline Plc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by GlycoMimetics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Glycostem Therapeutics BV, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Golden Biotechnology Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by H3 Biomedicine Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Hybrigenics SA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Igenica Biotherapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by IGF Oncology LLC, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Ignyta Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Immune Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Immune System Key Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by ImmunGene Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by ImmunoGen Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Immunomedics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Incyte Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Inflection Biosciences Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Innovation Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Interprotein Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Io Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Jasco Pharmaceuticals LLC, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Jazz Pharmaceuticals Plc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Johnson & Johnson, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by JW Pharmaceutical Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Kainos Medicine Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Kiadis Pharma NV, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Kite Pharma Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Komipharm International Co Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Kura Oncology Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Lead Discovery Center GmbH, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Les Laboratoires Servier SAS, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by MacroGenics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Mateon Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by MaxCyte Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by medac GmbH, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by MediGene AG, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by MedImmune LLC, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Medivir AB, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by MEI Pharma Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Merck & Co Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Merck KGaA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Merus NV, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Miltenyi Biotec GmbH, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by miRagen Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Mirati Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Moleculin Biotech Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by MolMed SpA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by NantKwest Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Nerviano Medical Sciences Srl, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Neumedicines Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by NewLink Genetics Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Novartis AG, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by NuCana BioMed Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Omeros Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by OncoImmune Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Onconova Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by OncoTartis Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by OncoTherapy Science Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Oncternal Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Otsuka Holdings Co Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Oxford BioTherapeutics Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by OXIS International Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Panacea Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Pfizer Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Pharma Mar SA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Pharmascience Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Pharmedartis GmbH, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Philogen SpA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Phylogica Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Plexxikon Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by PTC Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Rafael Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Resverlogix Corp, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Rich Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Rigel Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Sanofi, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Sareum Holdings Plc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Seattle Genetics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Selvita SA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Senhwa Biosciences Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Shire Plc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Sierra Oncology Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Sigma-Tau SpA, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Sorrento Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Spectrum Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Stemline Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Sunesis Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by SYNIMMUNE GmbH, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Syros Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by TaiGen Biotechnology Co Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Takara Bio Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Tolero Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Trillium Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Trovagene Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by VasGene Therapeutics Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Vichem Chemie Research Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Viralytics Ltd, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Xencor Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by Xenetic Biosciences Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline by ZIOPHARM Oncology Inc, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017 (Contd..2), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017 (Contd..3), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017 (Contd..4), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017 (Contd..5), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017 (Contd..6), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017 (Contd..7), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017 (Contd..8), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017 (Contd..9), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017 (Contd..10), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, H1 2017 (Contd..11), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Discontinued Products, H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Discontinued Products, H1 2017 (Contd..1), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Discontinued Products, H1 2017 (Contd..2), H1 2017

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Discontinued Products, H1 2017 (Contd..3), H1 2017

List of Figures

List of Figures

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports